ERBB2 and breast cancer: The German BC registry (TMK) cohort study included 1395 BC patients from February 2007 until October 2015 with HER2-positive patients showing a mean OS of 38.2 months, hormone receptor (HR) positive and HER2-negative patients of 33.8 months and triple-negative BC (TNBC) patients of only 16.8 months [9].